Martin Heidecker

Dr. Heidecker has 15 years of investment and commercial experience with venture capital and global pharmaceutical companies. He established the U.S.-office of Boehringer Ingelheim Venture Fund (BIVF) where he is focusing on biotech seed-investments. He previously held Senior Business Analyst and Director roles within the Global Business Analysis department, providing strategic marketing support for CNS, Women’s Health and Oncology. Prior to joining Boehringer Ingelheim (BI), Martin held several positions within the global Business Intelligence Department of Solvay Pharmaceuticals, focusing primarily on compounds in early clinical stages. Before Solvay, Martin was an investment manager at Bayern Kapital. During this time, he led co-investments in early stage drug development, medical devices, and bioinformatic companies. Dr. Heidecker holds a Ph.D. in Biology, focusing on membrane transport proteins in his thesis. He also has a Master’s degree in Biology and Economics.